ReviewKidney international2009
The kallikrein-kinin system in health and in diseases of the kidney.
Review in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 105 citations in OpenAlex.
- The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: the GenSalt Study.American journal of epidemiology · 2012Trial
- The Kininogen 1/bradykinin receptor B2 system serves as a key molecular response of vancomycin-induced nephrotoxicity and may be a potential target of absinthin.Histology and histopathology · 2026Article
- Association of prior Angiotensin receptor-neprilysin inhibitor use with the initial eGFR dip after initiation of SGLT2 inhibitors in patients with chronic kidney disease.Clinical and experimental nephrology · 2026Article
- Endothelial triple-pathway vasorelaxation as an adjunctive strategy in resistant hypertension.Journal of hypertension · 2026Review
- Preeclampsia Is a Double-Hit Vascular Disorder: The VEGF-HO-1-CSE Axis.Biomolecules · 2026Review
- Kallikrein-kinin system as a potential target for the treatment of intervertebral disc degeneration.European journal of medical research · 2025Review
- Article
- Integrated transcriptomic and single-cell RNA-seq analysis identifies CLCNKB, KLK1 and PLEKHA4 as key gene of AKI-to-CKD progression.Frontiers in immunology · 2025Article
- Analysis of IGHA1 and other salivary proteins post half marathon in female participants.PeerJ · 2023Article
- A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.Molecular biology reports · 2022Review
- A modular map of Bradykinin-mediated inflammatory signaling network.Journal of cell communication and signaling · 2022Article
- Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022Observational
- Review
- A Robust Bioassay of the Human Bradykinin BPharmaceuticals (Basel, Switzerland) · 2021Review
- Bradykinin Receptors Play a Critical Role in the Chronic Post-ischaemia Pain Model.Cellular and molecular neurobiology · 2021Article
- Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients.Frontiers in physiology · 2021Review
- Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.The review of diabetic studies : RDS · 2021Review
- A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes.Diabetologia · 2020Article
- COVID-19 Usurps Host Regulatory Networks.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Since kallikrein was discovered as a vasodilatory substance in human urine, the kallikrein-kinin system (KKS) has been considered to play a physiological role in controlling blood pressure. Gene targeting experiments in mice in which the KKS has been inactivated to varying degrees have, however, questioned this role, because basal blood pressures are not altered. Rather, these experiments have shown that the KKS has a different and important role in preventing changes associated with normal senescence in mice, and in reducing the nephropathy and accelerated senescence-associated phenotypes induced in mice by diabetes. Other experiments have shown that the KKS suppresses mitochondrial respiration, partly by nitric oxide and prostaglandins, and that this suppression may be a key to understanding how the KKS influences senescence-related diseases. Here we review the logical progression and experimental data leading to these conclusions, and discuss their relevance to human conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.